Navigation Links
Extending the effective lifetime of stents
Date:10/6/2011

Atherosclerosis is a major contributor to worldwide mortality and is characterized by narrowing of the arteries due to a thickening of the vessel wall. This restricts blood supply to the tissues and can lead to heart attack or stroke. In many cases, implantation of a stent can successfully be used for revascularization of the obstructed or stenosed arteries to improve blood flow. However, when a regrowth of cells occurs in the inner vessel wall (the intima) or healing of the endothelial cell lining in the vessel lumen is incomplete, the result can be a restenosis, i.e. recurrent arterial obstruction and restriction of blood flow.

A research team led by LMU's Professor Christian Weber has now shown that a specific cell type called neutrophils, and molecules that they secrete, inhibit this life-threatening complication which is observed in up to one-third of all stent implantations.

One of the products secreted by neutrophils, a short peptide named cathelicidin, promotes the healing of damaged blood vessels and patency of the stents by improving endothelial cell recovery, and prevents the formation of so-called neointima, which consists of cells of the inner vessel wall that contribute to restenosis at the site of stent implantation. Indeed, experiments in mice demonstrated that the incidence of restenosis was significantly reduced when miniaturized stents were coated with the peptide.

"Most modern stents release compounds aiming to block cell growth and inhibit inflammation nevertheless restenoses and other serious complications, such as thromboses, can still occur ," says Weber, Director of the Institute for Cardiovascular Prevention at Munich University Medical Center. "We hope that cathelicidin-coated stents have the expected effect in human subjects. Moreover, we plan to use our model systems to test the effects of other products secreted by neutrophils, as well as other peptides with similar functions to cathelicidin."


'/>"/>

Contact: Christian Weber
kreislaufinstitut@med.uni-muenchen.de
49-895-160-4351
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. Abcc10 may be effective in extending the effectiveness of anticancer drugs
2. Climate Change Extending Ragweed Season in Colder Climes: Study
3. Kings College London reveals promising techniques for extending the life of an organ transplant
4. Recession Causing Cancer Patients to Quit Life-Extending Drugs
5. Extending lifespan has mixed effects on learning and memory
6. Rising Use of Medical Technologies Extending Americans Lives
7. New research shows PET imaging effective in predicting lung cancer outcomes
8. Saw palmetto no more effective than placebo for urinary symptoms
9. Prevention of bedsores in long-term care homes cost-effective, study shows
10. Study examining large-scale data of double balloon enteroscopy shows it is safe and effective
11. Shorter radiation course for prostate cancer is effective in long-term follow-up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Demand ... at the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at ... more than 40 speakers — representing such thought-leading companies as JP Morgan ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... service and innovation, the company recently unveiled a redesigned website. The new site ... the work of building owners, architects, contractors and other industry users that Garland ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... variety of settings, gather for the National Athletic Trainers’ Association Annual Clinical Symposium ... case studies presented. It is also when Athletic Trainers are acknowledged by their ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey ... With Vaginas.” The goal is to ignite conversation via social media and word-of-mouth ... The brand has declared September “Humans with Vaginas” month, releasing a video celebrating ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and ... that it will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital ... three live 60-minute complimentary webinars on October 17, 2017 at 2 P.M. ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... Pa. , Sept. 5, 2017  Xyntek Inc. has announced another milestone ... a new Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 ... ... of customer engagements regionally. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology: